جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

26 مُخرَج نتائج البحث عن «Narrative review»

مقالوصول مفتوح20261استشهاد· Semantic Scholar

GLP-1 receptor agonists as potential disease-modifying agents in Parkinson’s and Alzheimer’s disease: mechanisms, clinical trial evidence, and the neuroprotection horizon

Frontiers in Aging Neuroscience · مجلد 18

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.

GLP-1 receptor agonistsParkinson's diseaseAlzheimer's diseasedisease-modifying therapy
مراجعةوصول مفتوح20261استشهاد· Semantic Scholar

A Review on Teledermatology in Saudi Arabia: Framework, Barriers, and Opportunities

INQUIRY The Journal of Health Care Organization Provision and Financing · مجلد 63 · 469580251405998-469580251405998

Teledermatology has become an important tool for expanding access to dermatologic care, especially in geographically large countries such as Saudi Arabia. Saudi Arabia's digital transformation and the shortage of dermatologists in rural regions have created favorable conditions for the adoption of teledermatology. Several platforms now provide virtual dermatology consultations. This narrative review aimed to explore teledermatology's current status, acceptance, barriers, and future directions in Saudi Arabia. The literature indicates that both dermatologists and patients are generally receptive to teledermatology, particularly for follow-up care; however, concerns about the lack of physical examination and reduced interpersonal interaction persist. A SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis revealed that Saudi Arabia's strong digital infrastructure, high smartphone penetration, and alignment with Vision 2030 are major strengths supporting teledermatology expansion. Key weaknesses include regulatory and reimbursement gaps, limited digital literacy, and the lack of dermatology-specific guidelines. Opportunities lie in extending services to underserved areas and integrating artificial intelligence, whereas threats include cultural resistance, cybersecurity risks, and potential inequities in digital access. In conclusion, teledermatology in Saudi Arabia is rapidly developing and shows considerable promise; however, its sustainability will depend on targeted investment, regulatory reforms, and efforts to promote equitable access.

teledermatologySaudi Arabiaaccess to dermatologic caretelehealth adoption barriers
مقالوصول مفتوح2026

Sleep-Disordered Breathing in Children with Down Syndrome in Saudi Arabia: Current Evidence and a Proposed Care Pathway

Children · مجلد 13 (11) · 1464-1464

Background/Objectives: Children with Down syndrome are at increased risk of obstructive sleep apnea (OSA), which cannot be reliably excluded by symptoms or examination. Saudi evidence remains limited. This review synthesizes international and Saudi evidence and proposes a pediatric care pathway incorporating the transition to adult services. Methods: We conducted a structured narrative review of the English-language literature identified through PubMed/MEDLINE, selected journal websites, and reference lists. The review focused on publications from January 2018 to 17 September 2026, retaining relevant earlier studies. Evidence was synthesized qualitatively without a new meta-analysis or formal risk of bias assessment. Results: Published international estimates indicate that OSA affects approximately 50–79% of children with Down syndrome. American Academy of Pediatrics guidance recommends polysomnography (PSG) at ages 3–4 years regardless of symptoms, with earlier assessment when indicated. Nonrandomized infant intervention studies suggest potential benefits but do not establish an optimal universal screening schedule. Saudi evidence includes a small earlier PSG referral cohort and more recent caregiver surveys; no nationally representative PSG-confirmed prevalence study was identified. Arabic questionnaire validation in a mixed pediatric referral cohort does not establish Down syndrome-specific diagnostic accuracy. Published treatment evidence indicates that adenotonsillectomy often improves OSA, although residual disease commonly requires objective reassessment and individualized management. Conclusions: The evidence supports age-based PSG, earlier assessment when indicated, postoperative reassessment, and individualized multidisciplinary care. Building on this evidence, we propose a Saudi pathway linking referral tracking, family-centered positive airway pressure support, and coordinated transition. Regional networks and registry development remain unevaluated implementation proposals requiring stakeholder consultation, resource assessment, and pilot testing; they do not constitute an endorsed national guideline.

Down syndromeobstructive sleep apneasleep-disordered breathingpolysomnography screening
مقالوصول مفتوح2026

Protracted Bacterial Bronchitis in Children: Clinical Presentation, Diagnostic Evaluation, and Evidence-Based Management

Cureus

Protracted bacterial bronchitis (PBB) is a treatable cause of chronic wet cough in children but is frequently missed.Unrecognized children often cycle through repeat asthma treatment, short antibiotic courses that do not address the infection, or open-ended reassurance without further evaluation.This review summarizes the clinical presentation, diagnostic criteria, differential diagnosis, treatment, and follow-up of PBB in children.We conducted a targeted narrative review (PubMed, through September 2026) of clinical trials, longitudinal studies, systematic reviews, and professional-society guidance, distinguishing evidence for antibiotic treatment from limited observational evidence linking recurrent PBB to bronchiectasis.Clinicians should suspect PBB in a child with a daily wet cough lasting more than four weeks and no findings indicating another cause.Resolution after an appropriate antibiotic course supports the diagnosis.Amoxicillinclavulanate remains the usual first-line treatment, typically for two weeks initially, with reassessment and selective extension to four weeks if the child has not cleared.Further investigation is warranted when symptoms persist despite adequate treatment, recurrence is frequent, or specific warning signs appear.In an otherwise typical, treatment-responsive case, bronchoscopy and chest computed tomography (CT) are not routine first steps.Management hinges on recognizing the wet-cough phenotype, giving an adequate therapeutic trial, confirming resolution, and investigating promptly when treatment fails.Antibiotics appear to improve cough resolution, but this rests on a small number of trials with limited certainty, and evidence that treatment itself prevents bronchiectasis remains thin.

protracted bacterial bronchitischronic wet coughpediatric respiratory infectionamoxicillin-clavulanic acid
مقالوصول مفتوح2026

Tavapadon in Parkinson’s disease: D1/D5 receptor pharmacology, clinical evidence, and translational perspectives

Frontiers in Aging Neuroscience · مجلد 18

Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.

Parkinson's diseasedopamine D1 receptordopamine D5 receptormotor fluctuations
مقالوصول مفتوح2026

Current Evidence and Clinical Controversies in the Management of Complicated Pneumonia in Children

American Journal of Pediatrics · مجلد 12 (3) · 87-102

Background: Parapneumonic effusion (PPE) and empyema remain serious complications of childhood pneumonia associated with significant morbidity despite advances in antimicrobial therapy and surgical techniques. Accurate disease staging and timely stage-directed intervention are fundamental to optimal outcomes. Objective: To provide a current, evidence-based synthesis of the definition, etiology, diagnosis, and management of complicated pneumonia in children, with particular focus on areas of ongoing clinical controversy. Methods: A narrative review incorporating randomized controlled trials, systematic reviews, meta-analyses, Cochrane reviews, and international clinical guidelines published between 2016 and 2026 was conducted. PubMed was searched through May 2026 using terms including pneumonia, complicated pneumonia, parapneumonic effusion, empyema, VATS, fibrinolysis, decortication, and pediatric. Results: Chest radiography remains the initial imaging modality for suspected complicated pneumonia, with lateral decubitus views needed to assess pleural fluid mobility. However, chest ultrasonography is the preferred imaging modality for evaluating parapneumonic effusions and empyema because of its superior diagnostic accuracy, ability to characterize pleural collections, and absence of ionizing radiation. Management is stage-dependent, combining targeted antibiotic therapy with procedural intervention when indicated. Image-guided pigtail catheter drainage with intrapleural fibrinolytic therapy is effective for most patients. VATS demonstrates particular utility during the fibrinopurulent stage. No single fibrinolytic agent has demonstrated clear superiority; however, tissue plasminogen activator is most widely employed. Open decortication remains reserved for refractory or advanced-stage disease. Conclusion: Early diagnosis, appropriate antibiotics, and prompt intervention or surgery are all important for optimal care. The optimal outcomes require a multidisciplinary, individualized, stage-directed approach. Interventional radiology is appropriate for single loculations, while early VATS is favored for thick pleural rind or multiple loculations. Further high-quality prospective research is needed to establish definitive treatment algorithms.

complicated pneumoniapediatric pneumoniaparapneumonic effusionempyema
مراجعةوصول مفتوح2026

Bone Mineral Density Changes and Metabolic Risk Factors in Patients with Rheumatoid Arthritis on Long-Term Therapy: A Narrative Review

International Journal of Clinical and Medical Research · مجلد 3 (1) · 22-26

Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease associated with progressive joint damage and important extra-articular complications, including osteoporosis, reduced Bone Mineral Density (BMD), fragility fractures, metabolic syndrome, insulin resistance, dyslipidemia, sarcopenia and cardiovascular disease. Chronic inflammation, reduced physical activity, altered body composition, nutritional deficiencies and long-term pharmacological therapy contribute to these complications. Glucocorticoids are particularly important because prolonged exposure may reduce bone formation and adversely affect glucose and lipid metabolism, although suppression of inflammation may partially counterbalance their skeletal effects. Disease-Modifying Antirheumatic Drugs (DMARDs), particularly biologic and targeted synthetic therapies, generally improve inflammatory control and may help preserve BMD but recent evidence suggests that bone loss can persist despite effective disease control. Metabolic syndrome is also common in RA and contributes substantially to cardiovascular risk. The relationship between RA and lipid abnormalities is complex because active inflammation may suppress circulating lipid concentrations despite increased cardiovascular risk. This narrative review summarizes current evidence regarding BMD changes, osteoporosis, glucocorticoid exposure, DMARD therapy, vitamin D status, metabolic abnormalities, sarcopenia and cardiovascular risk in patients receiving long-term treatment for RA. An integrated approach combining disease control, fracture-risk assessment, BMD monitoring, glucocorticoid minimization, metabolic screening, lifestyle modification and cardiovascular risk management is essential for comprehensive long-term care.

rheumatoid arthritisbone mineral densityosteoporosisglucocorticoid-induced osteoporosis
مراجعةوصول مفتوح2026

Beyond Lesion Control: A Narrative Review of Targeted Therapy and Surgical Decision-Making in Children With Vascular Anomalies Across Function, Growth, and Perioperative Care

Cureus · مجلد 18 (6) · e110532-e110532

Pediatric vascular anomalies are heterogeneous disorders that may cause pain, bleeding, infection, deformity, airway compromise, impaired mobility, psychosocial distress, and long-term functional morbidity. Surgery has traditionally played a central role in selected lesions through excision, debulking, staged reconstruction, and functional restoration. However, in children, operative decision-making is complicated by infiltrative anatomy, bleeding risk, lymphatic leakage, recurrence, scarring, growth potential, and the possibility of repeated procedures across childhood. The emergence of targeted therapies, particularly sirolimus for complex slow-flow malformations and alpelisib for PIK3CA-related overgrowth spectrum and selected vascular malformations, has shifted the management paradigm. These agents should not be viewed only as medical alternatives to surgery; rather, they may reshape surgical timing, extent, risk, and goals. This narrative review examines how targeted therapy may influence reconstructive surgical decision-making in children with vascular anomalies. We propose a child-centered model in which surgery may be performed, facilitated, delayed, avoided, or modified after targeted therapy. We also introduce the PERFORM framework to guide multidisciplinary assessment of patient age, lesion extent, treatment response, functional threat, operative risk, reconstruction required, and long-term follow-up. Future studies should move beyond radiologic response and report pediatric outcomes that matter: function, growth, quality of life, recurrence, revision surgery, and family burden.

pediatric vascular anomaliestargeted therapyrapamycinalpelisib
مراجعةمفتوح (مستودع)2026

Systemic lupus erythematosus in pregnancy: Maternal and fetal outcomes and management strategies (Review)

Medicine International · مجلد 6 (4) · 1-11

Systemic lupus erythematosus (SlE) is a chronic, multisystem, autoimmune disease that predominantly affects women during their reproductive years.Pregnancy in women with SlE is no longer considered uniformly prohibitive; however, it remains a high-risk clinical scenario due to maternal disease activity, lupus nephritis, antiphospholipid antibodies, chronic organ damage, and treatment-related factors that can adversely affect both maternal and fetal outcomes.Current evidence indicates that the risk of flare is highest in women who conceive with an active disease, discontinue effective therapy, or have a history of major organ involvement.at the same time, pregnancy introduces diagnostic complexity due to physiological gestational changes which may mimic lupus activity, particularly in hematological, renal and vascular domains.Maternal complications include preeclampsia, thromboembolism, infection, lupus nephritis exacerbation and postpartum flare, whereas fetal complications include miscarriage, fetal growth restriction, prematurity, neonatal lupus and congenital heart block in anti-ro/SSa-or anti-la/SSB-positive pregnancies.optimal management begins prior to conception and requires multidisciplinary care, risk stratification, medication optimization and structured maternal-fetal surveillance throughout pregnancy and the puerperium.the present narrative review summarizes contemporary evidence on the immunopathogenesis, preconception assessment, maternal and fetal risks, and therapeutic management of SlE in pregnancy, with an emphasis on clinically applicable strategies that improve patient outcomzes.Contents 1. Introduction 2. Pathogenesis of SlE 3. Effects of pregnancy on SlE 4. Pre-pregnancy counseling and considerations 5. Pre-pregnancy analyses in patients with SlE 6. Contraceptives in patients with SlE 7. Infertility in patients with SlE 8. Effects of SlE on pregnancy 9. Maternal complications associated with SlE 10.Placental disease in pregnancy in women with SlE and fetal complications of SlE 11.Puerperium 12. Medications for SlE during pregnancy 13.Biologics and emerging therapies 14.Conclusion

systemic lupus erythematosuspregnancymaternal complicationsfetal complications
مراجعةوصول مفتوح2026

Why Most Child Sexual Abuse Examinations Are Normal: Forensic Implications, Misconceptions, and Evidence-Based Communication

Cureus · مجلد 18 (3) · e105942-e105942

Child sexual abuse (CSA) evaluations frequently yield normal or nonspecific anogenital findings, even in cases later substantiated through investigation. This reality is often misunderstood in clinical, legal, and multidisciplinary contexts, where the absence of physical injury may be incorrectly interpreted as the absence of abuse. The purpose of this narrative review is to explain why most CSA examinations are normal and to provide an evidence-based framework for interpreting and communicating these findings in a manner that is medically accurate and forensically defensible. A targeted review of contemporary guidelines, large clinical series, healing studies, forensic evidence collection literature, and sexually transmitted infection (STI) testing recommendations was conducted. Evidence consistently demonstrates that low physical yield is driven by several converging factors: the nature of abusive acts, the elasticity and rapid healing capacity of pediatric anogenital tissues, delayed disclosure leading to non-acute examinations, variability in examiner experience and documentation quality, and the time-sensitive nature of biological evidence recovery. STI findings are uncommon overall and require contextual interpretation, including consideration of testing methods and potential nonsexual transmission pathways. Importantly, a normal examination neither confirms nor excludes CSA. Misinterpretation commonly arises from imprecise terminology, binary reasoning, and overreliance on physical findings as proof. This review emphasizes the need for standardized, evidence-based communication in medical reports and testimony to prevent medico-legal misunderstanding. Practical language guidance is provided to assist clinicians in accurately conveying the limitations and significance of normal findings. Understanding that "normal is common" in CSA evaluations is essential to reducing harm, supporting trauma-informed care, and strengthening the integrity of multidisciplinary decision-making.

child sexual abuseanogenital examinationnormal findingssexually transmitted infections
مراجعةمفتوح (مستودع)2026

The Impact of Body Weight on Aspirin’s Antiplatelet Efficacy: A Narrative Review of Conflicting Evidences and Clinical Implications

Advanced Health Science and Technology Journal · مجلد 2 (1) · 21-26

Abstract Aspirin is one of the oldest and most used anti-platelet medications for the prevention of cardiovascular diseases. There has been conflicting research recently about how body weight affects the antiplatelet effectiveness of aspirin. The purpose of this narrative review was to examine the recent research on the connection between aspirin responsiveness, platelet function, and obesity. To find patterns and discrepancies, pertinent research from PubMed, Scopus, and Google Scholar was rigorously examined and compiled. While some studies showed no discernible effect, others highlighted methodological and population-specific variations by reporting decreased aspirin efficacy in people with higher body weight because of increased platelet reactivity, aspirin deactivation, and altered pharmacokinetics, underscoring the need for well-designed, large-scale clinical investigations. The need for carefully planned, extensive clinical studies is highlighted by the fact that the evidence is still equivocal overall. A better understanding of these mechanisms may support the development of personalized antiplatelet strategies, including tailored aspirin dosing in selected subgroups such as obese patients with high thrombotic risk.

aspirinbody weightobesityantiplatelet efficacy
مراجعةوصول مفتوح202526استشهاد· Semantic Scholar

Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review

Cureus · مجلد 17 (1) · e78045-e78045

The rising demand for skin-lightening products has brought glutathione, a tripeptide with antioxidant properties and melanogenesis-regulating effects, into focus as a potentially safer alternative to conventional agents. This narrative review aims to evaluate the efficacy and safety of oral, topical, and intravenous glutathione in skin-lightening therapies. Oral administration shows significant but variable decreases in melanin levels with limited side effects. Topical formulations provide good-level melanin reduction and skin texture improvement but with varying sustainability. Intravenous glutathione, although having rapid action, is associated with serious safety concerns like anaphylaxis and hepatotoxicity, further aggravated by a lack of standardized dosing protocols. Current evidence supports glutathione's potential as a depigmenting agent but underscores the need for rigorous, large-scale clinical trials to establish long-term safety, optimal dosing, and standardized applications. Until such data are available, clinicians and consumers should exercise caution to ensure safe and effective dermatological practices, particularly with intravenous use.

glutathioneskin lighteningdepigmentationmelanogenesis
مراجعةوصول مفتوح20251استشهاد· Semantic Scholar

Inflammation-modulating agents in chronic limb-threatening ischemia: a narrative review of therapeutic potential and future directions

Annals of Medicine and Surgery · مجلد 88 (3) · 2298-2311

Chronic limb-threatening ischemia (CLTI) represents the most severe form of peripheral artery disease (PAD), driven by both advanced atherosclerosis and chronic inflammation. Despite advancements in revascularization and medical therapy, outcomes remain poor. Inflammation has emerged as a key therapeutic target, and several anti-inflammatory agents are under investigation for potential benefit in CLTI. A comprehensive literature review was conducted using PubMed, Scopus, Embase, Google Scholar, and Web of Science to identify studies published between 1990 and 2025. Keywords included "chronic limb-threatening ischemia," "peripheral artery disease," "colchicine," "canakinumab," "methotrexate," "NLRP3 inflammasome," and "anti-inflammatory therapy." Eligible studies included original research, clinical trials, systematic reviews, and relevant guidelines focused on inflammation-targeted interventions in atherosclerosis and limb ischemia. Colchicine has shown significant reductions in major adverse cardiovascular events in large trials and retrospective PAD studies, though no randomized controlled trials (RCTs) have specifically addressed CLTI. Canakinumab reduced inflammatory biomarkers and improved walking performance in PAD but had no effect on plaque progression. Methotrexate did not demonstrate cardiovascular benefit in the Cardiovascular Inflammation Reduction Trial. Preclinical agents targeting the NLRP3 inflammasome (e.g., MCC950) have shown anti-inflammatory effects but lack human data. Nutraceuticals, including omega-3 fatty acids and polyphenols, may offer adjunctive benefits, though evidence remains limited. Inflammation-modulating therapies hold promise as adjuncts in CLTI management, potentially improving outcomes by targeting the underlying immune mechanisms of disease progression. However, current evidence is insufficient for clinical adoption in CLTI. Large-scale, well-designed RCTs focusing on limb-specific outcomes are necessary to clarify the role of these therapies in high-risk vascular populations.

critical limb ischemiaperipheral arterial diseaseinflammationanti-inflammatory therapy